Effect of valspodar on the pharmacokinetics of unbound paclitaxel

Investigational New Drugs

Volumn 21, Issue 3, 2003, Pages 291-298

  Ten Tije, Albert J ^a   Synold, Timothy W ^b   Spicer, Darcy ^c   Verweij, Jaap ^a   Doroshow, James H ^b   Sparreboom, Alex ^a,d  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Disposition; P glycoprotein; Paclitaxel; Resistance; Valspodar

Indexed keywords

GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; PACLITAXEL; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; VALSPODAR;

ADULT; ADVANCED CANCER; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG HALF LIFE; HUMAN; MULTICENTER STUDY; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CYCLOSPORINS; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, INTRAVENOUS; MIDDLE AGED; P-GLYCOPROTEIN; PACLITAXEL; TIME FACTORS;

EID: 0345714781     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1025412509730     Document Type: Article

References (43)

1. Gottesman MM, Fojo T, Bates S: Multidrug resistance in cancer: role of AT-dependent transporters. Nature Rev Cancer 2: 48-58, 2002
2. Van Zuylen L, Nooter K, Sparreboom A, Verweij J: Development of multidrug-resistance convertors: sense or nonsense? Invest New Drugs 18: 205-220, 2000
3. Sparreboom A, Nooter K: Does P-glycoprotein play a role in anticancer drug pharmacokinetics? Drug Resis Updates 3: 357-363, 2000
4. Kroemer HK, Gautier JC, Beaune P, Henderson C, Wolf CR, Eichelbaum M: Identification of P450 enzymes involved in metabolism of verapamil in humans. Arch Pharmacol 348: 332-337, 1993
5. Kronbach T, Fischer V, Meyer UA: Cyclosporine metabolism in human liver: identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs. Clin Pharmacol Ther 43: 630-635, 1988
6. Fischer V, Rodriguez-Gaston A, Heitz F, Tynes R, Hauck C, Cohen D, Vickers AE: The multidrug resistance modulator valspodar (PSC 833) is metabolized by human cytochrome P450 3A: implications for drug-drug interactions and pharmacological activity of the main metabolite. Drug Metab Dispos 26: 802-811, 1998
7. Boesch D, Gaveriaux C, Jachezs B, Poutier-Manzanedo A, Bollinger P, Loor F: In vivo circumvention of P-glycoprotein mediated multidrug resistance of tumor cells with SDZ PSC 833. Cancer Res 51: 4226-4233, 1991
8. Boote D, Dennis P, Twentyman P, Osborne RJ, Hensel S, Smyth JF, Brampton MH, Bleehen NM: Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer. J Clin Oncol 14: 610-618, 1996
9. Giaccone G, Linn SC, Welink J, Catimel G, Stieltjes H, Van der Vijgh WJ, Eeltink C, Vermorken JB, Pinedo HM: A dose finding and pharmacokinetic study of reversal of multidrug resistance with PSC 833 in combination with doxorubicin in patients with solid tumors. Clin Cancer Res 3: 2005-2015, 1997
10. Harris JW, Rahman A, Kim BR, Guengerich FP, Collins JM: Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res 54: 4026-4035, 1994
11. Arzoo KK, Doroshow J, Frankel P, Gandara D, Groshen S, Muggia F, Russell C, Spicer DC, Synold T, Waisman J, Warner E: Valspodar (V) + paclitaxel (P) in advanced breast cancer: a California Cancer Consortium phase 11 randomized trial. Proc Am Soc Clin Oncol 19: 205a, 2000 (Abstract)
12. Brouwer E, Verweij J, De Bruijn P, Loos WJ, Pillay M, Buijs D, Sparreboom A: Measurement of fraction unbound paclitaxel in human plasma. Drug Metab Dispos 28: 1141-1145, 2000
13. Sparreboom A, De Bruijn P, Nooter K, Loos WJ, Stoter G, Verweij J: Determination of paclitaxel in human plasma using single solvent extraction prior to isocratic reversed-phase high-performance liquid chromatography with ultraviolet detection. J Chromatogr B 705: 159-164, 1998
14. Sparreboom A, Loos WJ, Verweij J, De Vos AI, Van der Burg MEL, Stoter G, Nooter K: Quantitation of Cremophor EL in human plasma samples using a colorimetric dye-binding microassay. Anal Biochem 255: 171-175, 1998
15. Brouwer E, Verweij J, Hauns B, Loos WJ, Nooter K, Mross K, Stoter G, Sparreboom A: Linearized colorimetric assay for Cremophor EL. application to pharmacokinetics after 1-hour paclitaxel infusions. Anal Biochem 261: 198-202, 1998
16. Henningsson A, Karlsson MO, Vigano L, Gianni L, Verweij J, Sparreboom A: Mechanism-based pharmacokinetic model for paclitaxel. J Clin Oncol 19: 4065-4073, 2001
17. Sparreboom A, Verweij J, Van der Burg MEL, Loos WJ, Brouwer E, Vigano L, Locatelli A, De Vos, AI, Nooter K, Stoter G, Gianni L: Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype. Clin Cancer Res 4: 1937-1942, 1998
18. Gelderblom H, Mross K, Ten Tije AJ, Behringer D, Mielke S, Van Zomeren DM, Verweij J, Sparreboom A: Comparative pharmacokinetics of unbound paclitaxel during 1- and 3-hour infusions. J Clin Oncol 20: 574-581, 2002
19. Smorenburg CH, Ten Tije AJ, Verweij J, Bontenbal M, Mross K, Van Zomeren DM, Seynaeve C, Sparreboom A: Altered clearance of unbound paclitaxel in elderly patients with metastatic breast cancer. Eur J Cancer 39: 196-202, 2003
20. Van Zuylen L, Gianni L, Verweij J, Mross K, Brouwer E, Loos WJ, Sparreboom A: Interrelationships of paclitaxel disposition, infusion duration and Cremophor EL kinetics in cancer patients. Anticancer Drugs 11: 3331-3337, 2000
21. Collins HL, Fisher GA, Hausdorff J, Lum BL, Pearce T, Halsey J, Sikic BI: Phase I study of paclitaxel in combination with SDZ PSC 833, a multidrug resistance modulator. Proc Am Soc Clin Oncol 14: 181a, 1995 (Abstract)
22. Fracasso PM, Westerveldt P, Fears CA, Rosen M, Zuhowski EG, Cazenave LA, Litchman M, Egorin MJ: Phase I study of paclitaxel in combination with a multidrug resistance modulator, PSC 833 (valspodar), in refractory malignancies. J Clin Oncol 18: 1124-1134, 2000
23. Patnaik A, Warner E, Michael M, Egorin MJ, Moore MJ, Siu LL, Fracasso PM, Rivkin S, Kerr I, Litchman M, Oza AM: Phase I dose-finding and pharmacokinetic study of paclitaxel and carboplatin with oral valspodar in patients with advanced solid tumors. J Clin Oncol 18: 3677-3689, 2000
24. Advani R, Fisher GA, Lum BL, Hausdorff J, Halsey J, Litchman M, Sikic BI: A phase I trial of doxorubicin, paclitaxel, and valspodar (PSC 833), a modulator of multidrug resistance. Clin Cancer Res 7: 1221-1229, 2001
25. Chico I, Kang MH, Bergan R, Abraham J, Bakke S, Meadows B, Rutt A, Robey R, Choyke P, Merino M, Goldspiel B, Smith T, Steinberg S, Figg WD, Fojo T, Bates S: Phase I study of infusional paclitaxel in combination with the P-glycoprotein antagonist PSC 833. J Clin Oncol 19: 832-842, 2001
26. Gianni L, Kearns CM, Giani A, Capri G, Vigano L, Locatelli A, Bonadonna G, Egorin MJ: Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 13: 180-190, 1995
27. Van Zuylen L, Karlsson MO, Verweij J, Brouwer E, De Bruijn P, Nooter K, Stoter G, Sparreboom A: Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles. Cancer Chemother Pharmacol 47: 309-318, 2001
28. Gelderblom H, Verweij J, Nooter K, Sparreboom A: Cremophor EL: the downsides and potential of vehicle selection for drug formulation. Eur J Cancer 37: 1587-1595, 2001
29. Van Zuylen L, Verweij J, Sparreboom A: Role of formulation vehicles in taxane pharmacology. Invest New Drugs 19: 125-141, 2001
30. Sparreboom A, Van Zuylen L, Brouwer E, Loos WJ, De Bruijn P, Gelderblom H, Pillay M, Nooter K, Stoter G, Verweij J: Cremophor EL mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res 59: 1454-1457, 1999
31. Sparreboom A, Van Tellingen O, Nooijen WJ, Beijnen JH: Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. Cancer Res 56: 2112-2115, 1996
32. Sparreboom A, Van Asperen J, Mayer U, Schinkel AH, Smit JW, Meijer DKF, Borst P, Nooijen WJ, Beijnen JH, Van Tellingen O: Limited oral bioavailability and active epithelial excretion of paclitaxel caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA 94: 2031-2035, 1997
33. Van Zuylen L, Sparreboom A, Van der Gaast A, Van der Burg MEL, Van Beurden V, Bol CJ, Woestenborghs R, Palmer PA, Verweij, J: The orally administered P-glycoprotein inhibitor R101933 does not alter the plasma pharmacokinetics of paclitaxel. Clin Cancer Res 6: 1365-1371, 2000
34. Van Zuylen L, Verweij J, Nooter K, Brouwer E, Stoter G, Sparreboom A: Role of intestinal P-glycoprotein in the plasma and fecal disposition of docetaxel in humans. Clin Cancer Res 6: 2598-2603, 2000
35. Kearns CM, Gianni L, Egorin MJ: Paclitaxel pharmacokinetics and pharmacodynamics. Semin Oncol 22: 16-23, 1995
36. Kang MH, Figg WD, Ando Y, Blagosklonny MV, Liewehr D, Fojo T, Bates SE: The P-glycoprotein antagonist PSC 833 increases the plasma concentrations of 6α-hydroxypaclitaxel, a major metabolite of paclitaxel. Clin Cancer Res 7: 1610-1617, 2001
37. Rahmani A, Korzekwa KR, Grohan J, Gonzalez FJ, Harris JW: Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8. Cancer Res 54: 5543-5546, 1994
38. Karlsson MO, Molnar V, Bergh J, Freijs A, Larsson R: A general model for time-dissociated pharmacokinetic-pharmacodynamic relationship exemplified by paclitaxel myelosuppression. Clin Pharmacol Ther 63: 11-25, 1998
39. Minami H, Sasaki Y, Saijo N, Ohtsu T, Fujii H, Igarashi T, Itoh K: Indirect-response model for the time course of leukopenia with anticancer drugs. Clin Pharmacol Ther 64: 511-521, 1998
40. Drach D, Zhao S, Drach J, Mahadevia R, Gattringer C, Huber H, Andreeff M: Subpopulations of normal blood and bone marrow cells express a functional multidrug resistance phenotype. Blood 80: 2729-2734, 1992
41. Tidefelt U, Liliemark J, Gruber A, Liliemark E, Sundman-Engberg B, Juliusson G, Stenke L, Elmhorn-Rosenborg A, Mollgard L, Lehman S, Xu D, Covelli A, Gustavsson B, Paul C: P-glycoprotein inhibitor valspodar (PSC 833) increases the intracellular concentrations of daunorubicin in vivo in patients with P-glycoprotein-positive acute myeloid leukemia. J Clin Oncol 18: 1837-1844, 2000
42. Lum BL, Kaubisch S, Fisher GA, Brown BW, Sikic BI: Effect of high-dose cyclosporine on etoposide pharmacodynamics in a trial to reverse P-glycoprotein (MDR1 gene) mediated drug resistance. Cancer Chemother Pharmacol 45: 305-311, 2000
43. Jachez B, Nordmann R, Loor F: Restoration of taxol sensitivity of multidrug-resistance cell by the cyclosporine SDZ PSC 833 and the cyclopeptolide SDZ 280-446. J Natl Cancer Inst 85: 478-483, 1993